NCT05322863

Brief Summary

To determine the efficacy of a 2-week daily programme (10 sessions) of HD-tDCS to augment antidepressant therapy in subjects with late-life depression who had residual depressive symptoms despite adequate dosage and duration of antidepressant therapy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
58

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 22, 2021

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

March 24, 2022

Completed
19 days until next milestone

First Posted

Study publicly available on registry

April 12, 2022

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 22, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

February 22, 2024

Completed
Last Updated

April 12, 2022

Status Verified

April 1, 2022

Enrollment Period

2 years

First QC Date

March 24, 2022

Last Update Submit

April 11, 2022

Conditions

Keywords

augmentation therapylate-life depression

Outcome Measures

Primary Outcomes (1)

  • Change in the Depressive symptoms

    the clinical response rate and the remission rate as measured with the HAM-D-17. A clinical response will be defined as a reduction of 50% or more in the HAM-D-17 score. A HAM-D-17 score of 7 or less will be used as an indicator of remission. Scores range from 0 to 52, with higher scores indicating more severe depression.

    Assessed at baseline, immediately after the intervention, and 4 and 12 weeks after the intervention.

Secondary Outcomes (8)

  • Change in the Global Cognition

    Assessed at baseline, immediately after the intervention, and 4 and 12 weeks after the intervention.

  • Change in the Working Memory

    Assessed at baseline, immediately after the intervention, and 4 and 12 weeks after the intervention.

  • Change in the Executive Functioning

    Assessed at baseline, immediately after the intervention, and 4 and 12 weeks after the intervention.

  • Change in the Verbal Fluency

    Assessed at baseline, immediately after the intervention, and 4 and 12 weeks after the intervention.

  • Change in the Attention

    Assessed at baseline, immediately after the intervention, and 4 and 12 weeks after the intervention.

  • +3 more secondary outcomes

Study Arms (2)

active HD-tDCS

ACTIVE COMPARATOR

The participants will be instructed to relax during the first 5 minutes of the session while the equipment is set up. A mild stimulation (with a level of only 2 milliamps stimulation) will be delivered for 20 minutes, with the current gradually increased and decreased over 30 seconds. The patients will be instructed to relax and remain motionless during the intervention. The administrator will closely monitor the impedance throughout each session and record any side effects experienced by the participants. The participants will be allowed 5 minutes of rest after the intervention and will be actively asked about any discomfort. Each session will last around 30 minutes, with a total of 10 sessions (two consecutive weeks of treatment for 5 days per week).

Device: High-definition Transcranial Direct Current Stimulation

sham-HD-tDCS

SHAM COMPARATOR

The procedure for sham stimulation will be identical, except that the current will be gradually ramped down to zero after the first 30 s, thus giving the same initial sensation of HD-tDCS. The stimulator will be programmed to switch the current on and off, so no intervention by the operator will be required. The computer will be placed behind the subjects' heads so they cannot see the readout.

Device: High-definition Transcranial Direct Current Stimulation

Interventions

The HD-tDCS will be administered by the program device called Starstim (Neuroelectrics). All participants will receive the treatment by using the same model of device. The HD-tDCS device can be portable and controlled wirelessly via computer software developed by the manufacturer. The montages will be a '4 × 1 ring set-up', which is the most commonly used HD-tDCS setting. The centre anode electrode is surrounded by four return cathode electrodes. The anode will be placed over the left dorsal lateral prefrontal cortex. Conductive electrode gel will be applied on the scalp at all designated electrode stimulation areas. A cap appropriate for each participants' head size will be used to ensure that the electrodes are secured in place. Impedance checks will be performed using the Starstim software before each treatment session.

active HD-tDCSsham-HD-tDCS

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age or above
  • Right-handedness, as determined by the Edinburgh Handedness Inventory (to homogenise neuroanatomical targeting)
  • Chinese ethnicity
  • Fulfil the criteria of Major Depressive Disorder (single or recurrent episode) and in partial remission, defined by the 5th Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
  • Presence of mild to severe level of depressive symptoms measured and defined by HAM-D-17 score ≥8 and ≤ 52\[22\]
  • Suboptimal treatment response with at least one adequate antidepressant trial defined as full or best tolerated doses at least 6 weeks
  • Stable dosage of antidepressants or other treatments for depression in recent 4 weeks
  • Valid informed written consent

You may not qualify if:

  • A DSM-5 diagnosis other than Depressive Disorders (e.g., bipolar and related disorders, schizophrenia spectrum and other psychotic disorders).
  • A Hong Kong Chinese version of the Montreal Cognitive Assessment (HK-MoCA) score below the second percentile according to the subject's age and education level (to exclude subjects with existing dementia)
  • Alcohol or substance dependence
  • Active suicidal ideation or a suicide attempt within the past month
  • Concomitant unstable medical condition or major neurological conditions
  • Significant communication impairment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Psychiatry, University of Hong Kong

Hong Kong, Hong Kong

RECRUITING

Related Publications (25)

  • Chi I, Yip PS, Chiu HF, Chou KL, Chan KS, Kwan CW, Conwell Y, Caine E. Prevalence of depression and its correlates in Hong Kong's Chinese older adults. Am J Geriatr Psychiatry. 2005 May;13(5):409-16. doi: 10.1176/appi.ajgp.13.5.409.

    PMID: 15879590BACKGROUND
  • Mitchell AJ, Subramaniam H. Prognosis of depression in old age compared to middle age: a systematic review of comparative studies. Am J Psychiatry. 2005 Sep;162(9):1588-601. doi: 10.1176/appi.ajp.162.9.1588.

    PMID: 16135616BACKGROUND
  • Schatzberg A, Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry. 2006 Apr;14(4):361-70. doi: 10.1097/01.JGP.0000194645.70869.3b.

    PMID: 16582045BACKGROUND
  • Blazer DG. Depression in late life: review and commentary. J Gerontol A Biol Sci Med Sci. 2003 Mar;58(3):249-65. doi: 10.1093/gerona/58.3.m249.

    PMID: 12634292BACKGROUND
  • World Health Organization. Depression. Fact sheet No. 369/October 2012

    BACKGROUND
  • Schulz R, Drayer RA, Rollman BL. Depression as a risk factor for non-suicide mortality in the elderly. Biol Psychiatry. 2002 Aug 1;52(3):205-25. doi: 10.1016/s0006-3223(02)01423-3.

    PMID: 12182927BACKGROUND
  • Baldwin RC. Refractory depression in late life: a review of treatment options. Rev Clin Gerontol. 1996;6(4):343-8.

    BACKGROUND
  • Alam M, Truong DQ, Khadka N, Bikson M. Spatial and polarity precision of concentric high-definition transcranial direct current stimulation (HD-tDCS). Phys Med Biol. 2016 Jun 21;61(12):4506-21. doi: 10.1088/0031-9155/61/12/4506. Epub 2016 May 25.

    PMID: 27223853BACKGROUND
  • Kuo HI, Bikson M, Datta A, Minhas P, Paulus W, Kuo MF, Nitsche MA. Comparing cortical plasticity induced by conventional and high-definition 4 x 1 ring tDCS: a neurophysiological study. Brain Stimul. 2013 Jul;6(4):644-8. doi: 10.1016/j.brs.2012.09.010. Epub 2012 Oct 13.

    PMID: 23149292BACKGROUND
  • Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton Depression Rating Scale. J Affect Disord. 2013 Sep 5;150(2):384-8. doi: 10.1016/j.jad.2013.04.028. Epub 2013 Jun 4.

    PMID: 23759278BACKGROUND
  • Kalu UG, Sexton CE, Loo CK, Ebmeier KP. Transcranial direct current stimulation in the treatment of major depression: a meta-analysis. Psychol Med. 2012 Sep;42(9):1791-800. doi: 10.1017/S0033291711003059. Epub 2012 Jan 12.

    PMID: 22236735BACKGROUND
  • Zheng YP, Zhao JP, Phillips M, Liu JB, Cai MF, Sun SQ, Huang MF. Validity and reliability of the Chinese Hamilton Depression Rating Scale. Br J Psychiatry. 1988 May;152:660-4. doi: 10.1192/bjp.152.5.660.

    PMID: 3167442BACKGROUND
  • Nikolin S, Huggins C, Martin D, Alonzo A, Loo CK. Safety of repeated sessions of transcranial direct current stimulation: A systematic review. Brain Stimul. 2018 Mar-Apr;11(2):278-288. doi: 10.1016/j.brs.2017.10.020. Epub 2017 Oct 31.

  • Das S, Holland P, Frens MA, Donchin O. Impact of Transcranial Direct Current Stimulation (tDCS) on Neuronal Functions. Front Neurosci. 2016 Nov 30;10:550. doi: 10.3389/fnins.2016.00550. eCollection 2016.

  • Fritsch B, Reis J, Martinowich K, Schambra HM, Ji Y, Cohen LG, Lu B. Direct current stimulation promotes BDNF-dependent synaptic plasticity: potential implications for motor learning. Neuron. 2010 Apr 29;66(2):198-204. doi: 10.1016/j.neuron.2010.03.035.

  • Brunoni AR, Kemp AH, Shiozawa P, Cordeiro Q, Valiengo LC, Goulart AC, Coprerski B, Lotufo PA, Brunoni D, Perez AB, Fregni F, Bensenor IM. Impact of 5-HTTLPR and BDNF polymorphisms on response to sertraline versus transcranial direct current stimulation: implications for the serotonergic system. Eur Neuropsychopharmacol. 2013 Nov;23(11):1530-40. doi: 10.1016/j.euroneuro.2013.03.009. Epub 2013 Apr 21.

  • Kuo HI, Paulus W, Batsikadze G, Jamil A, Kuo MF, Nitsche MA. Chronic Enhancement of Serotonin Facilitates Excitatory Transcranial Direct Current Stimulation-Induced Neuroplasticity. Neuropsychopharmacology. 2016 Apr;41(5):1223-30. doi: 10.1038/npp.2015.270. Epub 2015 Sep 2.

  • Javadi AH, Walsh V. Transcranial direct current stimulation (tDCS) of the left dorsolateral prefrontal cortex modulates declarative memory. Brain Stimul. 2012 Jul;5(3):231-241. doi: 10.1016/j.brs.2011.06.007. Epub 2011 Jul 26.

  • Mulquiney PG, Hoy KE, Daskalakis ZJ, Fitzgerald PB. Improving working memory: exploring the effect of transcranial random noise stimulation and transcranial direct current stimulation on the dorsolateral prefrontal cortex. Clin Neurophysiol. 2011 Dec;122(12):2384-9. doi: 10.1016/j.clinph.2011.05.009. Epub 2011 Jun 12.

  • Brunoni AR, Moffa AH, Fregni F, Palm U, Padberg F, Blumberger DM, Daskalakis ZJ, Bennabi D, Haffen E, Alonzo A, Loo CK. Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data. Br J Psychiatry. 2016 Jun;208(6):522-31. doi: 10.1192/bjp.bp.115.164715. Epub 2016 Apr 7.

  • Bares M, Brunovsky M, Stopkova P, Hejzlar M, Novak T. Transcranial Direct-Current Stimulation (tDCS) Versus Venlafaxine ER In The Treatment Of Depression: A Randomized, Double-Blind, Single-Center Study With Open-Label, Follow-Up. Neuropsychiatr Dis Treat. 2019 Oct 23;15:3003-3014. doi: 10.2147/NDT.S226577. eCollection 2019.

  • Loo CK, Husain MM, McDonald WM, Aaronson S, O'Reardon JP, Alonzo A, Weickert CS, Martin DM, McClintock SM, Mohan A, Lisanby SH; International Consortium of Research in tDCS (ICRT). International randomized-controlled trial of transcranial Direct Current Stimulation in depression. Brain Stimul. 2018 Jan-Feb;11(1):125-133. doi: 10.1016/j.brs.2017.10.011. Epub 2017 Oct 27.

  • Doruk D, Gray Z, Bravo GL, Pascual-Leone A, Fregni F. Effects of tDCS on executive function in Parkinson's disease. Neurosci Lett. 2014 Oct 17;582:27-31. doi: 10.1016/j.neulet.2014.08.043. Epub 2014 Aug 30.

  • Borckardt JJ, Bikson M, Frohman H, Reeves ST, Datta A, Bansal V, Madan A, Barth K, George MS. A pilot study of the tolerability and effects of high-definition transcranial direct current stimulation (HD-tDCS) on pain perception. J Pain. 2012 Feb;13(2):112-20. doi: 10.1016/j.jpain.2011.07.001. Epub 2011 Nov 21.

  • Ngan STJ, Chan LK, Chan WC, Lam LCW, Li WK, Lim K, Or E, Pang PF, Poon TK, Wong MCM, Wu YKA, Cheng PWC. High-definition transcranial direct current stimulation (HD-tDCS) as augmentation therapy in late-life depression (LLD) with suboptimal response to treatment-a study protocol for a double-blinded randomized sham-controlled trial. Trials. 2022 Oct 28;23(1):914. doi: 10.1186/s13063-022-06855-z.

Study Officials

  • Pak Wing Calvin Cheng

    The University of Hong Kong

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Pak Wing Calvin Cheng

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Assistant Professor

Study Record Dates

First Submitted

March 24, 2022

First Posted

April 12, 2022

Study Start

February 22, 2021

Primary Completion

February 22, 2023

Study Completion

February 22, 2024

Last Updated

April 12, 2022

Record last verified: 2022-04

Data Sharing

IPD Sharing
Will not share

Locations